Therapy for Lower Urinary Tract Dysfunctions

Patent metadata

Field	Value
Publication number	US-2018371046-A1
Application number	US-201815967986-A
Country	US
Kind code	A1
Filing date	May 1, 2018
Priority date	May 1, 2017
Publication date	Dec 27, 2018
Grant date	—

Abstract

The present invention relates to the use of relaxin for the treatment of lower urinary tract dysfunctions.

First claim

What is claimed is:

1 . A method for treating a lower urinary tract dysfunction comprising administering to a patient in need thereof an amount of a relaxin peptide effective to treat the lower urinary tract dysfunction.

2 . The method of claim 1 , wherein the lower urinary tract dysfunction is a fibrosis of the bladder.

3 . The method of claim 2 , wherein the fibrosis is radiation-induced cystitis.

4 . The method of claim 2 , wherein the fibrosis is chemical-induced cystitis.

5 . The method of claim 2 , wherein the fibrosis is interstitial cystitis.

6 . The method of claim 2 , wherein the fibrosis is age-related.

7 . The method of claim 1 , wherein the patient is male.

8 . The method of claim 1 , wherein the lower urinary tract dysfunction is benign prostate hyperplasia.

9 . The method of claim 1 , wherein the lower urinary tract dysfunction is under active bladder.

10 . The method of claim 1 , wherein the lower urinary tract dysfunction is over active bladder.

11 . The method of claim 1 , wherein the lower urinary tract dysfunction is caused by a spinal cord injury.

12 . The method of claim 1 , wherein the lower urinary tract dysfunction is prostatitis.

13 . The method of claim 1 , wherein the lower urinary tract dysfunction is caused by diabetes mellitus.

14 . The method of claim 1 , wherein the lower urinary tract dysfunction is recurrent urinary tract infections and/or chronic bacterial cystitis.

15 . The method of claim 1 , wherein the relaxin peptide is selected from human relaxin-1, human relaxin-2, or human insulin-like peptide-3.

16 . The method of claim 15 , wherein the relaxin peptide is human relaxin-2 such as a human relaxin-2 peptide having a sequence of SEQ ID NO: 1, or a sequence having 80%, 90%, 95%, 96%, 97%, 98%, 99% sequence identity to SEQ ID NO: 1.

17 . The method of claim 15 , wherein the relaxin peptide is human insulin-like peptide-3, such as a human insulin-like peptide-3 having a sequence of SEQ ID NO: 3, or a sequence having 80%, 90%, 95%, 96%, 97%, 98%, 99% sequence identity to SEQ ID NO: 3.

18 . The method of claim 1 , comprising administering to the patient from 1 μg/kg/day to 400 μg/kg/day of the relaxin peptide to the patient.

19 . The method of claim 1 , comprising administering the relaxin peptide via a parenteral route of administration to the patient.

20 . The method of claim 1 , comprising administering the relaxin peptide via a catheter to the patient.

Assignees

• Univ Pittsburgh Commonwealth Sys Higher Education

Inventors

• Kanai Anthony J
• Salama Guy
• Zabbarova Irina
• Ikeda Youko
• Weber Bethann

Classifications

• A61P13/02

  of urine or of the urinary tract, e.g. urine acidifiers · CPC title

• C07K14/64 Primary

  Relaxins · CPC title

• A61K9/0019 Primary

  Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00) · CPC title

• A61K38/2221

  Relaxins · CPC title

• C07K14/65

  Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2 · CPC title